# Exact Sciences

Type: Company (EXAS)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/exact-sciences
Canonical HTML page: https://gethealthbrief.com/entity/exact-sciences

## Timeline

- **2026-07-07**: Global Milestone Announcement — Gene Solutions issues press release detailing ASCO recognition, FDA designation, and IPO plans, marking a turning point for the company.
- **2026-07**: FDA Breakthrough Device Designation — The U.S. FDA grants Breakthrough Device Designation to SPOT-MAS 10, acknowledging its potential to address unmet needs in cancer screening.
- **2026-06**: ASCO Breakthrough 2026 — Gene Solutions presents interim real-world data from 84,145 asymptomatic individuals for SPOT-MAS 10 at the ASCO Breakthrough conference in Singapore.

## Recent coverage (4 stories)

### 84,145-Patient Study Propels Gene Solutions' SPOT-MAS 10 to Asian Cancer Screening Forefront
2026-07-22 05:19:29 · Sentiment: Strongly positive · Impact: 6/10 · Sources: 3

A massive real-world study and FDA Breakthrough Device Designation position SPOT-MAS 10 as a potential paradigm shift in multi-cancer screening across Asian healthcare systems, offering a non-invasive, population-validated tool to combat rising cancer burdens.
Full story: https://gethealthbrief.com/story/gene-solutions-spot-mas-asian-cancer-screening

### Abbott lifts 2026 EPS forecast to $5.45-$5.60 on 9% device growth
2026-07-17 03:46:04 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.
Full story: https://gethealthbrief.com/story/abbott-2026-profit-forecast-device-growth

### Mid-Cap Healthcare Stocks Hit Oversold Territory Amid Middle East Volatility
2026-03-17 14:53:42 · Sentiment: Negative · Impact: 6/10 · Sources: 3

A sharp sell-off in mid-cap healthcare stocks has pushed several key players into technically oversold territory as geopolitical tensions in the Middle East trigger a broader market retreat. Investors are rotating out of riskier mid-sized equities, creating potential entry points for value-oriented healthcare analysts.
Full story: https://gethealthbrief.com/story/mid-cap-healthcare-oversold-middle-east-volatility

### Mid-Cap Healthcare Stocks Surge in Quant Rankings Following Earnings Season
2026-03-14 15:35:12 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mid-cap healthcare stocks are seeing a significant re-rating as quantitative models prioritize profitable growth and upward analyst revisions. Following a strong earnings season, the diagnostic and med-tech sub-sectors have emerged as the primary drivers of sector outperformance.
Full story: https://gethealthbrief.com/story/mid-cap-healthcare-quant-rankings-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.